BioXcel - BTAI Net earnings per share growth forecast for next year

BioXcel Therapeutics leverages AI to develop neurological drugs, ensuring a steady cash flow. However, current revenues depend on the adoption rates of psychiatric treatments. The projected EPS trend for the coming year visualizes this balance, where 20.70 serves as the current metric level. Regulatory pressure from the FDA regarding expedited agitation therapy remains a constraining factor, which has triggered a temporary outflow of investment.

BioXcel (BTAI): Net earnings per share growth forecast for next year from 07/04/2022 to 09/19/2026

Summary analytical data breakdowns for bioxceltherapeutics.com (BTAI)

- price and consensus price forecast:

Price Chart BioXcel|BTAI - Fair Value Consensus

- issuer market value details:

Market Value BioXcel Therapeutics|BTAI - Total Enterprise Value

- company book value details:

Net Assets per Single Share BioXcel Therapeutics|BTAI - Company Book Value|Market Value to Book Value Ratio bioxceltherapeutics.com|BTAI - Company Assets

- issuer credit burden and liquidity indicators:

Total Debt to Capital BioXcel Therapeutics|BTAI - Long-Term Indebtedness to Equity|Short-Term Debt to Equity Ratio BioXcel Therapeutics, Inc.|BTAI - Company Cumulative Debt|Debts to Book Capitalization BioXcel Therapeutics|BTAI - Company Long-Term Debt|Company Short-Term Debts BioXcel Therapeutics|Quick Liquidity bioxceltherapeutics.com

- net income and valuation ratios data:

BTAI - Company Net Income|Future Profit BioXcel Therapeutics|BTAI - Price to Earnings Multiple|Forward P/E Multiple BioXcel Therapeutics|BTAI - Price/Earnings to Growth Multiple|EV/EBITDA Multiple BioXcel Therapeutics|BTAI - Profit before interest, taxes and amortization|Earnings per share for the last twelve months BioXcel Therapeutics|BTAI - Earnings per share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months bioxceltherapeutics.com|BTAI - Earnings per share increase in current year|Expected earnings per share growth for next year BioXcel Therapeutics

- company sales and revenue statistics:

BTAI - Company Total Sales|Projected Sales Volume BioXcel|BTAI - Market Capitalization-to-Revenue Ratio|Forward P/S Multiple BioXcel Therapeutics

Fundamental company analysis:BioXcel, BTAI

Finished products of BioXcel Therapeutics Inc

The reliability of equity assets is determined by a business's ability to generate future cash flow. This indicator measures the expected earnings per share (EPS) dynamics by comparing analyst consensus forecasts with historical values to strip inflationary noise from the data. For BioXcel Therapeutics (BTAI), this calculation reflects the efficiency of R&D cost reductions and the success of drug commercialization, making the EPS growth forecast trend a key signal of fundamental recovery.

Key competitors